GlassScriptPhysician profile
Kyla Beedy
NPI 1083921100
$53,688.27
in general payments reported to CMS, 2019-2025
35 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,429 · 2022: $9,999 · 2023: $28K · 2024: $8,953 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Travel and Lodging: $7,767 · Food and Beverage: $5,685 · Consulting Fee: $1,632 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,907.20 |
| Travel and Lodging | $7,766.76 |
| Food and Beverage | $5,685.10 |
| Consulting Fee | $1,632.00 |
| Education | $268.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $28,601.18 | 2021-2024 | Dupixent |
| Genzyme Corporation | $17,090.62 | 2021-2024 | |
| Inspire Medical Systems, INC. | $1,910.26 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $1,603.52 | 2021-2024 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $872.91 | 2021-2024 | Fasenra, Airsupra, Tezspire |
| Abbvie INC. | $755.18 | 2021-2025 | |
| Harmony Biosciences LLC | $507.52 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $420.69 | 2021-2024 | Ofev |
| Mylan Specialty L.P. | $409.80 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $272.40 | 2021-2024 | Aralast |
| Genentech USA, INC. | $256.74 | 2022-2024 | Xolair |
| Medtronic, INC. | $155.79 | 2024 | Signia |
| Sanofi-Aventis U.S. LLC | $133.95 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $99.48 | 2022-2024 | Opsumit |
| E.R. Squibb & Sons, L.L.C. | $50.24 | 2022-2024 | Eliquis |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $48.10 | 2021-2023 | Mavenclad |
| United Therapeutics Corporation | $46.67 | 2023-2024 | Tyvaso |
| Grifols USA, LLC | $43.77 | 2021-2024 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $38.91 | 2023-2024 | Sunosi |
| Merck Sharp & Dohme LLC | $37.83 | 2021-2024 | Winrevair |
| Baxter Healthcare | $33.91 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Jazz Pharmaceuticals INC. | $32.28 | 2021-2024 | |
| Philips North America LLC | $30.99 | 2022-2023 | |
| Vertex Pharmaceuticals Incorporated | $30.82 | 2025 | |
| Lilly USA, LLC | $26.88 | 2025 | Zepbound |
| Myriad Genetic Laboratories, INC. | $26.10 | 2023 | Precisetumor |
| Amgen INC. | $24.60 | 2023 | Tezspire |
| Inogen, INC. | $22.60 | 2022 | |
| Eisai INC. | $22.09 | 2024 | |
| Vapotherm INC | $17.44 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.73 | 2022 | |
| Insmed, INC. | $13.21 | 2023 | Arikayce |
| Sk Life Science, INC. | $12.64 | 2021 | |
| Amneal Pharmaceuticals LLC | $11.95 | 2021 | |
| Horizon Therapeutics Plc | $11.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyla Beedy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.